a multinational study that assessed the effectiveness of DA using the SilverHawkTM and TurboHawkTMPlaque ExcisionSystems (Covidien/ev3, Plymouth, MN) for treatment of peripheral arterial disease. Methods: The DEFINITIVE LE study enrolled 800 patients. Of those, 70 had CLI and at least one infrapopliteal target lesion treated with DA. Endpoints and adverse events were assessed by independent core laboratories and a Clinical Events Committee. The primary endpoint for the CLI cohort was freedom from major unplanned amputation of the target limb at 12 months. Results: Within the DEFINITIVE LE study, 70 patients with CLI had 96 infrapopliteal target lesions treated with DA. The breakdown by Rutherford Clinical Category (RCC) was as follows: RCC 4: 34%, RCC 5: 63%, and RCC 6: 3%.The mean age was74 years, 56% were male and79% had diabetes.The mean lesion length was 6.0 cm and the mean baseline stenosis was 77%. One-third (33%) of lesions were occluded,31% of lesions were calcified and 39% had inflow disease treated during the same procedure.Periprocedural complications included 1 (1%) perforation and 3 (4%) embolizations; there were no flow-limiting dissections. At 12 months, limb salvage was 94%, primary patency was 78% and freedom from target lesion revascularization (TLR) was 87%, per Kaplan-Meier estimates. Complete wound healing at 12 months was 68%. Conclusions: This prospective assessment of DA for treatment of Infrapopliteal lesions in CLI patients showed low complication rates and high rates of limb salvage,freedom from TLR, and primary patency at 12 months comparable to recent drug eluting stent trials. These findings should be taken into consideration when treating this challenging group of patients.
Background: The EGO-COMBO study is the first study ever designed to establish the healing profile of a DES, and benefits of the dual therapy COMBO Stent (OrbusNeich, US), a hybrid version of the EPC-capturing Genous Stent plus a 5mg/ mm abluminal sirolimus coating, using sequential OCT FUs to 24 months. Methods: In this prospective single center study, 61 patients (9M DAPT) received 3 longitudinal sequential OCTs at baseline (for optimal stent apposition), at early FU (4 monthly group 2nd to 5th month, in 1:2:2:1 ratio, for % strut coverage using 6 Categories), then at 9M (for late loss and OCT neointima), and clinical FU to 12M. With a 2nd approved protocol, a 24M OCT FU was initiated for long term outcomes. Conclusions: Using stringent longitudinal sequential OCT FUs with core lab. adjudication, the dual therapy COMBO stent is the first DES ever with a healing profile established and appears to be a novel device (excellent healing with optimal neointimal suppression without late stent thrombosis) with durable 24M outcomes. This longitudinal sequential OCT FU approach may be adopted to guide development of any new stent platform, appropriate DAPT duration, and to predict (prevent) late stent thrombosis.
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